Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA. / Doritchamou, Justin; Nielsen, Morten A.; Chêne, Arnaud; Viebig, Nicola K.; Lambert, Lynn E.; Sander, Adam F.; Semblat, Jean Philippe; Hundt, Sophia; Orr-Gonzalez, Sachy; Janitzek, Christoph Mikkel; Spiegel, Alicia J.; Clemmensen, Stine B.; Thomas, Marvin L.; Nason, Martha C.; Snow-Smith, Maryonne; Barnafo, Emma K.; Shiloach, Joseph; Chen, Beth B.; Nadakal, Steven; Highsmith, Kendrick; Ouahes, Tarik; Conteh, Solomon; Sharma, Ankur; Torano, Holly; Butler, Brandi; Reiter, Karine; Rausch, Kelly M.; Scaria, Puthupparampil V.; Anderson, Charles; Narum, David L.; Salanti, Ali; Fried, Michal; Theander, Thor G.; Gamain, Benoit; Duffy, Patrick E.

In: Lab Animal, Vol. 52, No. 12, 2023, p. 315-323.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Doritchamou, J, Nielsen, MA, Chêne, A, Viebig, NK, Lambert, LE, Sander, AF, Semblat, JP, Hundt, S, Orr-Gonzalez, S, Janitzek, CM, Spiegel, AJ, Clemmensen, SB, Thomas, ML, Nason, MC, Snow-Smith, M, Barnafo, EK, Shiloach, J, Chen, BB, Nadakal, S, Highsmith, K, Ouahes, T, Conteh, S, Sharma, A, Torano, H, Butler, B, Reiter, K, Rausch, KM, Scaria, PV, Anderson, C, Narum, DL, Salanti, A, Fried, M, Theander, TG, Gamain, B & Duffy, PE 2023, 'Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA', Lab Animal, vol. 52, no. 12, pp. 315-323. https://doi.org/10.1038/s41684-023-01274-2

APA

Doritchamou, J., Nielsen, M. A., Chêne, A., Viebig, N. K., Lambert, L. E., Sander, A. F., Semblat, J. P., Hundt, S., Orr-Gonzalez, S., Janitzek, C. M., Spiegel, A. J., Clemmensen, S. B., Thomas, M. L., Nason, M. C., Snow-Smith, M., Barnafo, E. K., Shiloach, J., Chen, B. B., Nadakal, S., ... Duffy, P. E. (2023). Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA. Lab Animal, 52(12), 315-323. https://doi.org/10.1038/s41684-023-01274-2

Vancouver

Doritchamou J, Nielsen MA, Chêne A, Viebig NK, Lambert LE, Sander AF et al. Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA. Lab Animal. 2023;52(12):315-323. https://doi.org/10.1038/s41684-023-01274-2

Author

Doritchamou, Justin ; Nielsen, Morten A. ; Chêne, Arnaud ; Viebig, Nicola K. ; Lambert, Lynn E. ; Sander, Adam F. ; Semblat, Jean Philippe ; Hundt, Sophia ; Orr-Gonzalez, Sachy ; Janitzek, Christoph Mikkel ; Spiegel, Alicia J. ; Clemmensen, Stine B. ; Thomas, Marvin L. ; Nason, Martha C. ; Snow-Smith, Maryonne ; Barnafo, Emma K. ; Shiloach, Joseph ; Chen, Beth B. ; Nadakal, Steven ; Highsmith, Kendrick ; Ouahes, Tarik ; Conteh, Solomon ; Sharma, Ankur ; Torano, Holly ; Butler, Brandi ; Reiter, Karine ; Rausch, Kelly M. ; Scaria, Puthupparampil V. ; Anderson, Charles ; Narum, David L. ; Salanti, Ali ; Fried, Michal ; Theander, Thor G. ; Gamain, Benoit ; Duffy, Patrick E. / Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA. In: Lab Animal. 2023 ; Vol. 52, No. 12. pp. 315-323.

Bibtex

@article{8ed73c008df14568b6b8ecc046933846,
title = "Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA",
abstract = "Placental malaria vaccines (PMVs) are being developed to prevent severe sequelae of placental malaria (PM) in pregnant women and their offspring. The leading candidate vaccine antigen VAR2CSA mediates parasite binding to placental receptor chondroitin sulfate A (CSA). Despite promising results in small animal studies, recent human trials of the first two PMV candidates (PAMVAC and PRIMVAC) generated limited cross-reactivity and cross-inhibitory activity to heterologous parasites. Here we immunized Aotus nancymaae monkeys with three PMV candidates (PAMVAC, PRIMVAC and ID1-ID2a_M1010) adjuvanted with Alhydrogel, and exploited the model to investigate boosting of functional vaccine responses during PM episodes as well as with nanoparticle antigens. PMV candidates induced high levels of antigen-specific IgG with significant cross-reactivity across PMV antigens by enzyme-linked immunosorbent assay. Conversely, PMV antibodies recognized native VAR2CSA and blocked CSA adhesion of only homologous parasites and not of heterologous parasites. PM episodes did not significantly boost VAR2CSA antibody levels or serum functional activity; nanoparticle and monomer antigens alike boosted serum reactivity but not functional activities. Overall, PMV candidates induced functional antibodies with limited heterologous activity in Aotus monkeys, similar to responses reported in humans. The Aotus model appears suitable for preclinical downselection of PMV candidates and assessment of antibody boosting by PM episodes.",
author = "Justin Doritchamou and Nielsen, {Morten A.} and Arnaud Ch{\^e}ne and Viebig, {Nicola K.} and Lambert, {Lynn E.} and Sander, {Adam F.} and Semblat, {Jean Philippe} and Sophia Hundt and Sachy Orr-Gonzalez and Janitzek, {Christoph Mikkel} and Spiegel, {Alicia J.} and Clemmensen, {Stine B.} and Thomas, {Marvin L.} and Nason, {Martha C.} and Maryonne Snow-Smith and Barnafo, {Emma K.} and Joseph Shiloach and Chen, {Beth B.} and Steven Nadakal and Kendrick Highsmith and Tarik Ouahes and Solomon Conteh and Ankur Sharma and Holly Torano and Brandi Butler and Karine Reiter and Rausch, {Kelly M.} and Scaria, {Puthupparampil V.} and Charles Anderson and Narum, {David L.} and Ali Salanti and Michal Fried and Theander, {Thor G.} and Benoit Gamain and Duffy, {Patrick E.}",
note = "Publisher Copyright: {\textcopyright} 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",
year = "2023",
doi = "10.1038/s41684-023-01274-2",
language = "English",
volume = "52",
pages = "315--323",
journal = "Lab Animal",
issn = "0093-7355",
publisher = "nature publishing group",
number = "12",

}

RIS

TY - JOUR

T1 - Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

AU - Doritchamou, Justin

AU - Nielsen, Morten A.

AU - Chêne, Arnaud

AU - Viebig, Nicola K.

AU - Lambert, Lynn E.

AU - Sander, Adam F.

AU - Semblat, Jean Philippe

AU - Hundt, Sophia

AU - Orr-Gonzalez, Sachy

AU - Janitzek, Christoph Mikkel

AU - Spiegel, Alicia J.

AU - Clemmensen, Stine B.

AU - Thomas, Marvin L.

AU - Nason, Martha C.

AU - Snow-Smith, Maryonne

AU - Barnafo, Emma K.

AU - Shiloach, Joseph

AU - Chen, Beth B.

AU - Nadakal, Steven

AU - Highsmith, Kendrick

AU - Ouahes, Tarik

AU - Conteh, Solomon

AU - Sharma, Ankur

AU - Torano, Holly

AU - Butler, Brandi

AU - Reiter, Karine

AU - Rausch, Kelly M.

AU - Scaria, Puthupparampil V.

AU - Anderson, Charles

AU - Narum, David L.

AU - Salanti, Ali

AU - Fried, Michal

AU - Theander, Thor G.

AU - Gamain, Benoit

AU - Duffy, Patrick E.

N1 - Publisher Copyright: © 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

PY - 2023

Y1 - 2023

N2 - Placental malaria vaccines (PMVs) are being developed to prevent severe sequelae of placental malaria (PM) in pregnant women and their offspring. The leading candidate vaccine antigen VAR2CSA mediates parasite binding to placental receptor chondroitin sulfate A (CSA). Despite promising results in small animal studies, recent human trials of the first two PMV candidates (PAMVAC and PRIMVAC) generated limited cross-reactivity and cross-inhibitory activity to heterologous parasites. Here we immunized Aotus nancymaae monkeys with three PMV candidates (PAMVAC, PRIMVAC and ID1-ID2a_M1010) adjuvanted with Alhydrogel, and exploited the model to investigate boosting of functional vaccine responses during PM episodes as well as with nanoparticle antigens. PMV candidates induced high levels of antigen-specific IgG with significant cross-reactivity across PMV antigens by enzyme-linked immunosorbent assay. Conversely, PMV antibodies recognized native VAR2CSA and blocked CSA adhesion of only homologous parasites and not of heterologous parasites. PM episodes did not significantly boost VAR2CSA antibody levels or serum functional activity; nanoparticle and monomer antigens alike boosted serum reactivity but not functional activities. Overall, PMV candidates induced functional antibodies with limited heterologous activity in Aotus monkeys, similar to responses reported in humans. The Aotus model appears suitable for preclinical downselection of PMV candidates and assessment of antibody boosting by PM episodes.

AB - Placental malaria vaccines (PMVs) are being developed to prevent severe sequelae of placental malaria (PM) in pregnant women and their offspring. The leading candidate vaccine antigen VAR2CSA mediates parasite binding to placental receptor chondroitin sulfate A (CSA). Despite promising results in small animal studies, recent human trials of the first two PMV candidates (PAMVAC and PRIMVAC) generated limited cross-reactivity and cross-inhibitory activity to heterologous parasites. Here we immunized Aotus nancymaae monkeys with three PMV candidates (PAMVAC, PRIMVAC and ID1-ID2a_M1010) adjuvanted with Alhydrogel, and exploited the model to investigate boosting of functional vaccine responses during PM episodes as well as with nanoparticle antigens. PMV candidates induced high levels of antigen-specific IgG with significant cross-reactivity across PMV antigens by enzyme-linked immunosorbent assay. Conversely, PMV antibodies recognized native VAR2CSA and blocked CSA adhesion of only homologous parasites and not of heterologous parasites. PM episodes did not significantly boost VAR2CSA antibody levels or serum functional activity; nanoparticle and monomer antigens alike boosted serum reactivity but not functional activities. Overall, PMV candidates induced functional antibodies with limited heterologous activity in Aotus monkeys, similar to responses reported in humans. The Aotus model appears suitable for preclinical downselection of PMV candidates and assessment of antibody boosting by PM episodes.

U2 - 10.1038/s41684-023-01274-2

DO - 10.1038/s41684-023-01274-2

M3 - Journal article

C2 - 37932470

AN - SCOPUS:85175798368

VL - 52

SP - 315

EP - 323

JO - Lab Animal

JF - Lab Animal

SN - 0093-7355

IS - 12

ER -

ID: 373884387